Add BrightSurf on Google Email

Children’s Hospital of Philadelphia researchers report encouraging first evidence of effective new gene therapy to treat multiple sulfatase deficiency

Children's Hospital of Philadelphia researchers have reported encouraging evidence of an effective new gene therapy to treat multiple sulfatase deficiency. The ex vivo gene therapy improved sulfatase production and reduced symptoms associated with the disease in preclinical models.

SourceChildren's Hospital of Philadelphia·JournalMolecular Therapy·TypeExperimental study·DateSep 9, 2024

Solving the side effect problem of siRNA drugs for genetic disease treatment using formamide

Researchers at Nagoya University have developed a method to chemically alter siRNAs, reducing off-target effects and improving the safety of siRNA drugs for genetic therapy. By modifying the seed region of siRNAs with formamide, they achieved suppression of off-target effects with higher efficiency than existing chemical modifications.

SourceNagoya University·JournalNucleic Acids Research·DateSep 6, 2024

UVA research cracks the autism code, making the neurodivergent brain visible

A multi-university research team led by University of Virginia engineering professor Gustavo K. Rohde has developed a system that can accurately spot genetic markers of autism in brain images. The system uses generative computer modeling technique called transport-based morphometry, which reveals brain structure patterns that predict v...

Machine learning approach helps researchers design better gene-delivery vehicles for gene therapy

Researchers at the Broad Institute of MIT and Harvard developed a machine-learning approach to design better AAVs for gene therapy. The tool helps engineer capsids with multiple desirable traits, such as targeting specific organs or working in multiple species. About 90% of predicted capsids successfully delivered cargo to human liver ...

SourceBroad Institute of MIT and Harvard·JournalNature Communications·DateAug 8, 2024

'Gene misbehavior' widespread in healthy people

A recent study found that 'gene misbehaviour' is a common phenomenon in the healthy human population, with over half of inactive genes showing misexpression. The researchers used advanced techniques to analyze blood samples from 4,568 healthy individuals and identified mechanisms behind these gene activity errors.

SourceWellcome Trust Sanger Institute·JournalAmerican Journal of Human Genetics·TypeObservational study·DateJul 24, 2024

Effectiveness of using siRNA to treat Huntington’s disease

A new study published in Nucleic Acid Therapeutics found that siRNA reduces huntingtin mRNA levels in the cytoplasm but not in the nucleus of mouse brains, suggesting a limitation in its effectiveness for treating Huntington's disease. The research highlights the importance of understanding the structure and function of nuclear RNA to ...

SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalNucleic Acid Therapeutics·TypeExperimental study·DateJul 22, 2024

Researchers evaluate the benefit of dual therapy for children at risk for spinal muscular atrophy

A first-of-its-kind study compared preventative therapy efficacy between two groups: gene therapy alone and in combination with risdiplam or nusinersen. Dual therapy showed promise in independent sitting outcomes, but not in walking age or muscle disease progression prevention.

SourceClinic for Special Children·JournalAnnals of Clinical and Translational Neurology·TypeObservational study·DateJun 25, 2024

Researchers discover potential mole reversal therapy in rare condition

Researchers at Francis Crick Institute develop a new genetic therapy that silences mutated NRAS gene in cells with congenital melanocytic naevus syndrome (CMN), potentially reversing debilitating giant moles. The treatment has shown promising results in mice and could be used to reduce cancer risk in affected children and adults.

SourceThe Francis Crick Institute·JournalJournal of Investigative Dermatology·DateJun 17, 2024

New Gene therapy trial shows restored hearing and speech in children born deaf, treated in both ears

A novel gene therapy has restored hearing function in five children with DFNB9 who were treated in both ears, demonstrating additional benefits compared to a previous trial. The treatment also improved speech perception and sound localization abilities, including the ability to appreciate music.

SourceMass Eye and Ear·JournalNature Medicine·TypeRandomized controlled/clinical trial·DateJun 5, 2024

Identification of key of transposable elements associated with myocarditis based on RNA and single-cell sequencing data mining

A study utilizing RNA-Seq and single-cell RNA-Seq data identified key transposable elements (TEs) linked to myocarditis. These findings reveal a significant role for TEs in modulating immune responses, providing new insights into cardiomyopathy's pathogenesis.

SourceKeAi Communications Co., Ltd.·JournalReproduction and Breeding·TypeData/statistical analysis·DateMay 15, 2024

Real-world data fills knowledge gap to assess treatment options for infants with spinal muscular atrophy, showing improved outcomes

A study in the Journal of Neuromuscular Diseases found that disease-modifying gene therapy treatments improve motor function, bulbar function, and pulmonary function in infants with spinal muscular atrophy. The real-world data from a large patient registry confirms improved safety profiles for early treatment opportunities.

SourceIOS Press·JournalJournal of Neuromuscular Diseases·TypeData/statistical analysis·DateApr 15, 2024

An immunotherapy to overcome resistant leukemia

Researchers have discovered a new immunotherapy approach to overcome resistant leukemia by targeting the mutated TP53 gene. Combining pharmacological therapies with genetically engineered CAR T-cells increases effectiveness against cancer cells, offering promising strategies for patients with resistant disease.

SourceUniversity of Zurich·JournalEMBO Molecular Medicine·TypeExperimental study·DateMar 21, 2024

Experimental gene therapy for giant axonal neuropathy shows promise in NIH clinical trial

A clinical trial at NIH demonstrated that experimental gene therapy slowed loss of motor function in patients with giant axonal neuropathy, a fatal childhood disease. The treatment also showed signs of regeneration in sensory nerves, offering new hope for those affected.

SourceNIH/National Institute of Neurological Disorders and Stroke·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateMar 20, 2024

Researchers develop artificial building blocks of life

Scientists from the University of Cologne developed threofuranosyl nucleic acid (TNA) with a new base pair, offering improved stability and function compared to natural DNA and RNA. This breakthrough could enable targeted drug delivery, diagnostics, and recognition of viral proteins or biomarkers.

SourceUniversity of Cologne·JournalJournal of the American Chemical Society·TypeExperimental study·DateMar 8, 2024